An underground market for unapproved slimming medications is propelled by social media fitness personalities and sellers on communication apps, according to new investigations.
Experimental Drug Gaining Popularity Via Social Media
The experimental drug, which remains in clinical trials, is being promoted by social media influencers for its alleged fat-burning properties. Followers are encouraged to contact these profiles directly for source information, while also receiving promotional offers.
Thriving Commerce on Messaging Platforms
Separately, a robust market exists on Telegram, where groups with thousands of participants share comparison photos, administration instructions and assertions of rapid British shipping. Sellers promote the drug there before directing customers to WhatsApp for transactions.
Learning About Retatrutide
Retatrutide is an investigational injectable developed by American pharmaceutical company Eli Lilly. The treatment targets three gut hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon. Preliminary studies suggest it could help individuals lose up to a quarter of their total weight. Referred to as the “triple G”, the drug is being hailed online as the next Ozempic.
Healthcare Experts Express Concerns
Nevertheless, doctors and chemists have cautions that the sale of what is still an unapproved drug in the United Kingdom is worrisome and could result in individuals administering products of uncertain source.
Some experts said the demand for retatrutide could be linked to the rising price of licensed slimming treatments such as Mounjaro.
Legal Status and Enforcement
Marketing retatrutide on social media or Telegram is illegal in the United Kingdom, as it is an unapproved drug that must not be promoted or supplied for personal consumption under the Human Medicines Regulations 2012.
Several content creators try to circumvent the regulations by calling to the substance as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a restricted drug, but promotion and distribution can still violate pharmaceutical, advertising, and consumer laws, risking penalties, legal action or prison.
Service Reaction and Content Removal
Based on TikTok, the service has taken down problematic content and prohibited related keywords and search suggestions. The company stated it was committed to keeping the service secure and investing in strengthening compliance measures.
Online Marketplace Operations
Research also found communities with up to nine thousand members marketing retatrutide using the platform's built-in search feature, which operates like a public directory. Typing “retatrutide” immediately brings up groups with thousands of users, filled with images of slimming results, positive reviews and step-by-step guides for mixing or administering at residence.
Within minutes of entering one group, a vendor shared WhatsApp details, where the majority of purchases take place. The seller provided an instruction manual and guaranteed delivery within two days. When asked whether the product was genuine, one seller said: “You can’t be sure.” Another shared a image of a supposed testing documentation. None asked about weight, medical conditions or past usage.
Item Information and Pricing
Inside these groups, posts show black plastic parcels with postal service stickers, claiming to include new batches. One communication read: “It took eight of us to load them this morning.”
Buyers can choose between dry substance containers, prepared at residence with sterile water, or pre-filled pens usually priced at £160 for 20 milligrams. When questioned how long a injector should last, sellers give conflicting responses varying between a several days to “depends on your body”.
Platform Moderation and Safety Measures
A spokesperson for the messaging service said it regularly monitored harmful material on its service including material that promoted the “misuse of controlled medications”. The company added that it removed “millions of pieces of harmful content each day”.
Medical Expert Cautions
“Individuals are injecting substances they can’t verify. Even if the research behind retatrutide is sound, these digital versions may not include what they advertise,” said Jason Murphy, the head of pharmaceutical services at a pharmacy service.
Dr Crystal Wyllie of an online medical service linked the increase in interest to recent cost increases for approved weight-loss medications such as Mounjaro. “With prices increasing, patients are using social media. But counterfeit treatments are extremely dangerous. You cannot know what’s inside or whether the conditions they were made in was sterile,” she explained.
Her staff has previously encountered patients injured by personal administration from unverified suppliers. “We understand the disappointment, but buying from messaging apps or communication platforms is gambling with your well-being,” said Wyllie. “These substances could be impure or improperly measured.”
Manufacturer Position
A representative from Eli Lilly stated retatrutide was in phase 3 research studies and had not been evaluated or authorized by any regulatory agency globally. “Therefore at this point no one can market [it] for human use,” they explained, adding that any item “falsely representing itself as a company experimental substance not yet approved … may expose patients to possibly significant medical dangers”.
